Breaking News

Financial Report: Alexion

February 14, 2013

Solaris sales climb 41% in the quarter


4Q Revenues: $320.5 million (+41%)

4Q Earnings: $81.0 million (+68%)

FY Revenues: $1.1 billion (+45%)

FY Earnings: $254.8 million (+45%)

Comments: Soliris sales were $320.5 million in the quarter, up 41%, and $1.1 billion for the year, up 45% driven by steady additions of new patients with paroxysmal nocturnal hemoglobinuria (PNH) globally, and an increasing number of new patients with atypical Hemolytic Uremic Syndrome (aHUS).
blog comments powered by Disqus
  • Staying Ahead in the Small Molecule Space

    Staying Ahead in the Small Molecule Space

    Dr. Matthew Moorcroft, VP Global Marketing, Cambrex||September 8, 2016
    Understand what is happening in the market and react accordingly

  • FDA & Drug Development

    FDA & Drug Development

    Rachelle Du2019Souza, Regulatory Heights Inc.||September 8, 2016
    You must perform the necessary due diligence to stay on top of regulatory developments

  • Patent Law  and Contract Manufacturing

    Patent Law and Contract Manufacturing

    Beverly W. Lubit, Member of the Firm, Chiesa Shahinian & Giantomasi||September 8, 2016
    Analyzing the impact of The Medicines Co. vs. Hospira Inc. decision